H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on BiomX (PHGE) today and set a price target of $20.00. The company’s shares closed last Wednesday at $7.12.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 42.4% and a 64.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BiomX with a $20.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.07 and a one-year low of $4.52. Currently, BiomX has an average volume of 66.88K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.